There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

There are more than 300 GLP-1Rs in an active stage of development, from industry giants and potential market disrupters.

triggering the release of glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in regulating blood sugar levels. This study was made available online on November 5, 2024 ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) rose 5.6% on Thursday . The company traded as high as $29.87 and last traded at $29.84. Approximately 85,014 shares changed hands during mid ...

The median percentage of spending on pharmacy rose from 21% in 2021 to 27% in 2023, fueled in no small part by the popularity of glucagon-like ... are very close in structure and function to ...

Principal Financial Group Inc. increased its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 230.0% in the third quarter, according to the company in its most recent ...

Sarhan and his colleague Steven Klein at the Caron Treatment Centers in Florida and Pennsylvania have prescribed a range of so-called glucagon ... is quite similar in structure to exenatide ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...

Sarhan and his colleague Steven Klein at the Caron Treatment Centers in Florida and Pennsylvania have prescribed a range of so-called glucagon ... is quite similar in structure to exenatide ...